In addition, an experimental compound, elafibranor (a PPARα/δ dual agonist) specifically designed for cardiometabolic diseases, has been tested in clinical trials in patients with NAFLD/NASH. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.